Skip to content

About us
Inobrodib
News
- Press releases
- Publications
Contact us

About us
Inobrodib
News
- Press releases
- Publications
Contact us

ASCO, Chicago (2017)

Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of CRPC

Applications

Inobrodib is currently being evaluated for safety and effectiveness in multiple specific settings

Multiple Myeloma

Haematological malignancies, and specifically multiple myeloma (MM), are regulated in part by p300/CBP.

Other Applications

Acute Myeloid Leukaemia (AML), Lymphomas, Solid tumours and Targeted Tumours.

About CellCentric

CellCentric is a clinical stage biotech company focused on the development of a first of its kind, p300/CBP inhibitor to treat specific cancer types.

Quick Links

About us
Inobrodib
Clinical trials
Publications
Our story

Menu

About us
Inobrodib
Clinical trials
Publications
Our story

Our team
Press releases
News
Contact
Expanded Access Policy
Privacy Policy

Menu

Our team
Press releases
News
Contact
Expanded Access Policy
Privacy Policy

Follow us

Follow us and stay up to date with our latest news, events and scientific posters.

Icon-x Linkedin-in

© CellCentric Limited 2024 | Company #4948632

Main Menu

About us
Inobrodib
News
- Press releases
- Publications
Contact us

Follow us on LinkedIn